FDA Committee to Review Moderna's mRNA Flu Vaccine

An FDA advisory committee is set to convene today to evaluate Moderna's mRNA influenza vaccine, MFLUSIVA. The committee will discuss the vaccine's safety and effectiveness for individuals aged 50 and older. Their recommendations will be crucial for the vaccine's potential approval.